Camila Câmara

By Avril Daly, President, EURORDIS — Rare Diseases Europe For decades, Europe has been losing ground in the global competition for life sciences investment, research, and development. The Biotech Act I proposal is an important part of an effort to reverse this trend, which is why it has been welcomed by Europe’s rare disease community with enthusiasm. The case for boosting Europe’s biotech sector is both moral and strategic. The unmet needs are enormous.

By Juan Carlos Jaramillo, MD - Chief Medical Officer of Valneva SE Europe cannot afford to rediscover preparedness only when the next crisis arrives. COVID-19 exposed deep vulnerabilities in health security, manufacturing capacity and supply chains, but the lesson goes far beyond a single pandemic.

By Stine Bosse, Member of the European Parliament (Renew Europe - Denmark) – Vice-Chair SANT Committee Today, European patients wait on average more than 578 days to access new medicines after approval from the European Medicines Agency with a significant variation between the EU member states. At the same time, less than half of innovative medicines approved between 2020 and 2023 were available for patients in 2024.